Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Next Previous
X
Search
Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimekizumab (Primary) ; Ustekinumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms BE VIVID
  • Sponsors UCB Biopharma

    • Most Recent Events

    • 15 Jun 2024 Results assessing impact of Bimekizumab on cardiovascular inflammation-associated markers over 16 weeks from BE RADIANT trial and over 48 weeks from BE RADIANT trial presented at the 25th Annual Congress of the European League Against Rheumatism
    • 09 Mar 2024 Results of pooled analysis((BE SURE, BE VIVID, and BE READY) announced in presentations of BIMZELX (bimekizumab-bkzx) four-year efficacy and safety data in the treatment of adults with moderate to severe plaque psoriasis are being shared this week at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, March 8 to 12, in the UCB Media Release.
    • 10 Nov 2023 Results of pooled analysis from NCT03412747, NCT03370133, NCT03410992, NCT03598790 assessing bimekizumab's 3-year safety profile in patients with moderate to severe plaque psoriasis published in the British Journal of Dermatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top